LOXL2 and cancer: Blocking the interaction between LOXL2 and PEAR1 with a PEAR1-EMI monoclonal antibody significantly inhibited TNBC metastasis both in vitro and in vivo, indicating that PEAR1 is the major receptor mediating the nonenzymatic activity of LOXL2 in cancer metastasis and that the LOXL2/PEAR1 axis is a promising target for TNBC therapy.